Genentech is committed to supporting programs open to a broad audience that benefit patients, the scientific or medical community and/or public health.
Genentech is committed to supporting our existing grantees during the evolving coronavirus (COVID-19) pandemic. We understand that grantees will have their own challenges in adapting to rapidly changing events, and we will work to accommodate needs for the programs funded by Genentech.
If you are an existing grantee, please contact your Genentech representative with questions or to let us know if your program or event will be cancelled or postponed. If you are unsure of who to contact, please email [email protected] and we will direct you to the appropriate person.
To learn more about Genentech’s efforts during the pandemic, please visit our COVID-19 response page.
These support requests are healthcare-related and are consistent with a therapeutic or technological area in which Genentech or Roche is active.
Grant requests must be submitted at least 60 days prior to the project/program start date. The following uploads are required to submit your application:
Before you start the submission process, please be sure to have the following information available:
If your application is approved, you will need to enter into a Letter of Agreement (LOA) with Genentech. You will have to provide the name and email address of a contact at your organization who would be legally authorized to sign the LOA before you can complete submission.
An event/program that will occur on multiple dates and/or in multiple locations can be submitted in one request. For example, a nationwide charity walk series can be submitted in one request because each charity walk is a component of one event/program.
Funding Request System Resources
For more information on the funding request process, click here.
Your organization must be recognized by the IRS as a tax exempt, public charity under sections 501(c)(3) and 501(c)(6) of the Internal Revenue Code and be located in the United States (or have W8-BEN status if not located in the United States); or be a US governmental organization (such as public schools, public colleges and universities, public hospitals and federally recognized Indian tribal governments).
Genentech/Roche will consider funding requests in the following disease states:
In order to be eligible for this type of funding, your organization must not be:
In order to be eligible for this type of funding, the funding must not be used for:
Genentech does not show preference in decision-making for funding requests with volunteering opportunities, however if a volunteer opportunity is available, it must be open to the public. Genentech cannot be the sole supporter of an event or program.
For patient programs and for scientific or medical meeting support, the funding must also follow the following criteria:
An organization with a written policy to discriminate based on race, religion, gender, gender expression and/or identity, age, national origin, disability, marital status, sexual orientation, military status, or any other protected status is ineligible for funding.
Genentech has a rolling review policy when evaluating funding requests for healthcare-related charitable support. This allows qualified requestors the opportunity to apply anytime during year.
Requests must be submitted at least 60 days prior to the project/program start date. Decisions are made on a case-by-case basis; you will usually hear back from Genentech prior to the project/program start date. Please refrain from submitting applications for which the project/program start date is more than 6 months out. Early submissions will not ensure an early decision.
All grants must abide by the terms in the Genentech Letter of Agreement (LOA), which is issued to an
authorized signer of your organization once the application is approved. You must agree to the terms
of the LOA before any funding is issued.
If you have any questions on the agreement terms, please email us at [email protected] or call (877) 313-5778.
Note: The funding application site does not support IE8 or earlier